EUVIMEDEUVIMED entdecken
Open Access

Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023

Ruth Link-Gelles, Allison Avrich Ciesla, Elizabeth A K Rowley, Nicola P Klein, Allison L Naleway, Amanda B Payne, Anupam Kharbanda, Karthik Natarajan, Malini B DeSilva, Kristin Dascomb, Stephanie A Irving, Ousseny Zerbo und 22 weitere

MMWR. Morbidity and Mortality Weekly Report · 2023

DOI: 10.15585/mmwr.mm7233a2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift MMWR. Morbidity and Mortality Weekly Report, 2023. Verfasst von Ruth Link-Gelles und 33 weiteren Autor:innen. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On June 19, 2022, the original monovalent mRNA COVID-19 vaccines were approved as a primary series for children aged 6 months-4 years (Pfizer-BioNTech) and 6 months-5 years (Moderna) based on safety, immunobridging, and limited efficacy data from clinical trials. On December 9, 2022, CDC expanded recommendations for use of updated bivalent vaccines to children aged ≥6 months. mRNA COVID-19 vaccine effectiveness (VE) against emergency department or urgent care (ED/UC) encounters was evaluated within the VISION Network during July 4, 2022-June 17, 2023, among children with COVID-19-like illness aged 6 months-5 years. Among children aged 6 months-5 years who received molecular SARS-CoV-2 testing during August 1, 2022-June 17, 2023, VE of 2 monovalent Moderna doses against ED/UC encounters was 29% (95% CI = 12%-42%) ≥14 days after dose 2 (median = 100 days after dose 2; IQR = 63-155 days). Among children aged 6 months-4 years with a COVID-19-like illness who received molecular testing during September 19, 2022-June 17, 2023, VE of 3 monovalent Pfizer-BioNTech doses was 43% (95% CI = 17%-61%) ≥14 days after dose 3 (median = 75 days after dose 3; IQR = 40-139 days). Effectiveness of ≥1 bivalent dose, comparing children with at least a complete primary series and ≥1 bivalent dose to unvaccinated children, irrespective of vaccine manufacturer, was 80% (95% CI = 42%-96%) among children aged 6 months-5 years a median of 58 days (IQR = 32-83 days) after the dose. All children should stay up to date with recommended COVID-19 vaccines, including initiation of COVID-19 vaccination immediately when they are eligible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19United StatesChildHumansCOVID-19 VaccinesVaccines, CombinedCOVID-19 TestingSARS-CoV-2Emergency Service, HospitalRNA, MessengermRNA Vaccines

Substanzen

COVID-19 VaccinesVaccines, CombinedRNA, MessengermRNA Vaccines

Zitieren

APA

Link-Gelles, R., Ciesla, A. A., Rowley, E. A. K., Klein, N. P., Naleway, A. L., Payne, A. B., Kharbanda, A., Natarajan, K., DeSilva, M. B., Dascomb, K., Irving, S. A., Zerbo, O., Reese, S. E., Wiegand, R. E., Najdowski, M., Ong, T. C., Rao, S., Stockwell, M. S., Stephens, A., …, & Fleming-Dutra, K. E. (2023). Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023. MMWR. Morbidity and Mortality Weekly Report. https://doi.org/10.15585/mmwr.mm7233a2

Vancouver

Link-Gelles R, Ciesla AA, Rowley EAK, Klein NP, Naleway AL, Payne AB, et al. Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023. MMWR. Morbidity and Mortality Weekly Report. 2023. doi:10.15585/mmwr.mm7233a2

BibTeX
@article{LinkGelles2023,
  author = {Link-Gelles, Ruth and Ciesla, Allison Avrich and Rowley, Elizabeth A K and Klein, Nicola P and Naleway, Allison L and Payne, Amanda B and Kharbanda, Anupam and Natarajan, Karthik and DeSilva, Malini B and Dascomb, Kristin and Irving, Stephanie A and Zerbo, Ousseny and Reese, Sarah E and Wiegand, Ryan E and Najdowski, Morgan and Ong, Toan C and Rao, Suchitra and Stockwell, Melissa S and Stephens, Ashley and Goddard, Kristin and Martinez, Yessica C and Weber, Zachary A and Fireman, Bruce and Hansen, John and Timbol, Julius and Grannis, Shaun J and Barron, Michelle A and Embi, Peter J and Ball, Sarah W and Gaglani, Manjusha and Grisel, Nancy and Arndorfer, Julie and Tenforde, Mark W and Fleming-Dutra, Katherine E},
  title = {Effectiveness of Monovalent and Bivalent mRNA Vaccines in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters Among Children Aged 6 Months–5 Years — VISION Network, United States, July 2022–June 2023},
  journal = {MMWR. Morbidity and Mortality Weekly Report},
  year = {2023},
  doi = {10.15585/mmwr.mm7233a2}
}
Kostenlos starten →